Intelligence Feed event · Policy · 2026-08-30

    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026

    Question

    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026

    Direct answer

    Cytokinetics (CYTK) presented late-breaking clinical trial findings for its cardiac myosin inhibitor, aficamten (MYQORZO), at the European Society of Cardiology (ESC) Congress 2026. The ACACIA-HCM study demonstrated significant improvements in cardiac structure and diastolic function among patients suffering from non-obstructive hypertrophic cardiomyopathy (HCM). Additionally, MAPLE-HCM data reinforced the drug's efficacy profile, strengthening Cytokinetics' competitive positioning in the cardiovascular therapeutic landscape against existing standard-of-care treatments.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-30
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026”, revision 1, evidence through 2026-08-30. https://marketontology.com/market-events/2026-08-30/cytokinetics-presents-aficamten-phase-3-data-at-esc-congress-2026-6897dd

    POLICY
    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026
    Cytokinetics (CYTK) presented late-breaking clinical trial findings for its cardiac myosin inhibitor, aficamten (MYQORZO), at the European Society of Cardiology (ESC) Congress 2026. The ACACIA-HCM study demonstrated significant improvements in cardiac structure and diastolic function among patients suffering from non-obstructive hypertrophic cardiomyopathy (HCM). Additionally, MAPLE-HCM data reinforced the drug's efficacy profile, strengthening Cytokinetics' competitive positioning in the cardiovascular therapeutic landscape against existing standard-of-care treatments.
    CYTKBMY
    Impact
    73
    AUG 30
    SIG
    89%
    CYTKBMY
    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026
    Cytokinetics (CYTK) presented late-breaking clinical trial findings for its cardiac myosin inhibitor, aficamten (MYQORZO), at the European Society of Cardiology (ESC) Congress 2026. The ACACIA-HCM study demonstrated significant improvements in cardiac structure and diastolic function among patients suffering from non-obstructive hypertrophic cardiomyopathy (HCM). Additionally, MAPLE-HCM data reinforced the drug's efficacy profile, strengthening Cytokinetics' competitive positioning in the cardiovascular therapeutic landscape against existing standard-of-care treatments.
    → Positive late-breaking clinical data for aficamten expands its addressable market into non-obstructive HCM, enhancing commercial revenue projections for Cytokinetics.
    Impact
    Cytokinetics (CYTK) presented late-breaking clinical trial findings for its cardiac myosin inhibitor, aficamten (MYQORZO), at the European Society of Cardiology (ESC) Congress 2026. The ACACIA-HCM study demonstrated significant improvements in cardiac structure and diastolic function among patients suffering from non-obstructive hypertrophic cardiomyopathy (HCM). Additionally, MAPLE-HCM data reinforced the drug's efficacy profile, strengthening Cytokinetics' competitive positioning in the cardiovascular therapeutic landscape against existing standard-of-care treatments.
    Affected
    CYTKBMY
    Transmission
    Positive late-breaking clinical data for aficamten expands its addressable market into non-obstructive HCM, enhancing commercial revenue projections for Cytokinetics.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CYTKcommercial pipeline addressable market expansionUp1-5dAficamten demonstrated structural cardiac improvement in late-breaking clinical trials at ESC Congress.
    BMYcompetitive positioning in hypertrophic cardiomyopathy therapiesMixed1-4wBristol Myers Squibb markets competing cardiac myosin inhibitor Camzyos.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month